Lemtrada (alemtuzumab) works by wiping out most of the immune cells responsible for attacking the brain and spinal cord in multiple sclerosis, then allowing the immune system to rebuild itself in a way that’s less likely to cause damage. It targets a protein called CD52, which sits on the surface of immune cells, and essentially triggers those cells to self-destruct. The result is a near-complete depletion of certain white blood cells, followed by a slow regrowth process that reshapes the immune system’s behavior for years.
How Lemtrada Depletes Immune Cells
In MS, the immune system mistakenly attacks the protective coating around nerve fibers in the brain and spinal cord. Two types of white blood cells drive this attack: T cells and B cells. Both carry the CD52 protein on their surface, and Lemtrada locks onto that protein like a key fitting a lock. Once attached, it flags the cell for destruction by the body’s own cleanup mechanisms.
Within days of an infusion, circulating T cells and B cells drop to near zero. This stops the immune assault on nerve tissue quickly and thoroughly. It’s a far more aggressive approach than most MS therapies, which is why Lemtrada is typically reserved for people with relapsing MS who haven’t responded well to other treatments.
The Immune System Rebuilds Differently
The depletion phase is only half the story. What makes Lemtrada unusual among MS drugs is what happens next: the immune system slowly repopulates, and the new immune cells behave differently than the ones that were destroyed.
B cells bounce back first, returning to normal levels (or even higher) within 3 to 6 months. T cells take much longer, typically 1 to 3 years, and their numbers often remain below pre-treatment levels even after recovery. This matters because the rebuilt T cell population tends to be shifted toward a more anti-inflammatory profile. Research published in Frontiers in Immunology found that the reconstituted immune system showed increased regulatory control over the specific inflammatory T cells most associated with MS damage. In other words, the immune cells that regrow are less aggressive toward the body’s own tissue.
This rebalancing is why Lemtrada’s effects last far beyond the infusion days themselves. The rebuilt immune system maintains a more tolerant state for years, which is the basis for calling the treatment an “immune reset.”
The Infusion Schedule
Lemtrada is given as an intravenous infusion in two treatment courses, spaced 12 months apart. The first course runs for 5 consecutive days, with a total dose of 60 mg. The second course is shorter: 3 consecutive days, totaling 36 mg. Each infusion takes several hours, and you’ll be monitored during and after for reactions.
Most people experience infusion reactions during treatment, ranging from headache and rash to fever and nausea. These are common enough that premedication is given before each session to reduce their severity. The reactions are typically manageable and tend to be worst during the first course.
After these two rounds, many patients don’t need additional treatment for years. Some never need a third course. This “treat and walk away” model is one of Lemtrada’s biggest appeals compared to daily pills or monthly injections required by other MS therapies.
How Well It Controls MS
Clinical trials comparing Lemtrada to a standard injectable MS therapy found that it cut the annualized relapse rate roughly in half. In the CARE-MS II trial, which enrolled people who had already relapsed on a prior treatment, Lemtrada reduced the relapse rate to 0.26 per year compared to 0.52 for the comparison drug.
The benefits held up over time. In years 3 through 5 of follow-up, the annual relapse rate stayed low (ranging from 0.18 to 0.23), and the proportion of patients showing no evidence of disease activity climbed to about 58% by year 5. That means well over half of patients had no relapses, no new brain lesions on MRI, and no worsening disability, all without additional treatment during that period.
The Autoimmune Trade-Off
Lemtrada’s biggest risk is also a consequence of how it works. When the immune system rebuilds, it sometimes develops new autoimmune problems, essentially misfiring in a different direction. The most common target is the thyroid gland.
About one-third of people treated with Lemtrada develop autoimmune thyroid disease. A systematic review in the Journal of Pioneering Medical Sciences found the overall incidence was 32.3% across more than 1,400 patients, with rates ranging from 23% to 41% depending on the study. Graves’ disease, which causes an overactive thyroid, was the most frequent type, accounting for 33% to 65% of thyroid cases. Hashimoto’s thyroiditis, which causes an underactive thyroid, was the second most common.
Less frequently, Lemtrada can trigger immune thrombocytopenia (a condition where the immune system destroys blood platelets) or kidney problems. These are rarer but potentially serious. This is why anyone taking Lemtrada commits to years of regular blood and urine tests after treatment, typically monthly, to catch these complications early when they’re most treatable. Thyroid problems, for instance, are very manageable when detected quickly but can cause significant symptoms if missed.
Why the Immune Reset Isn’t Perfect
The same research that documented Lemtrada’s benefits also revealed that the rebuilt immune system isn’t flawless. While regulatory T cells increase their control over the inflammatory cells linked to MS, the body’s ability to regulate B cells actually decreases after treatment. The ratio between certain helper and regulatory immune cells shifts in a way that leaves B cells less supervised than before.
This imbalance likely explains the high rate of secondary autoimmune conditions. The immune system becomes better at leaving nerve tissue alone but simultaneously becomes more prone to attacking other organs. It’s a trade-off that makes Lemtrada a powerful option for aggressive MS but one that requires careful, long-term monitoring to manage safely.
Who Lemtrada Is Designed For
Because of its risk profile, Lemtrada is not a first-line treatment. It’s approved for relapsing forms of MS in people who have had an inadequate response to two or more other MS drugs. The FDA restricts its distribution through a special program that ensures both patients and prescribers understand the monitoring requirements before starting.
For the right candidate, someone with active relapsing MS that keeps breaking through other therapies, Lemtrada offers something most MS treatments don’t: the possibility of long-term disease control from just two short courses of treatment, without the need for continuous medication. That potential comes with real risks, but for many patients, the math works out in Lemtrada’s favor.